IP Library Granted Patent US 10,434,116
Granted Patent B2
US 10,434,116 · App. 15/302,915 · Granted Oct 8, 2019

Methods of treating coronavirus infection

Inventors: Matthew Frieman (Hunt Valley, MD); Peter B. Jarhling (Gaithersburg, MD); Lisa E. Hensley (Frederick, MD)
Assignees: University of Maryland, Baltimore; United States Government as represented by the Secretary, Department of Health and Human Services
A61K31/7068A61K31/13A61K31/138A61K31/435A61K31/46A61K31/4706A61K31/4709A61K31/496A61K31/506A61K31/522A61K31/5415A61K31/55A61K31/662A61K31/675A61K31/7012A61K31/7056A61K31/7072A61K31/7125A61K38/21A61K38/212A61K38/215A61K38/217A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,434,116
App. No.
15/302,915
Filed
Oct 7, 2016
Granted
Oct 8, 2019
Kind
B2
Art Unit
1649
USPC
424/85.5
Abstract

The present invention provides methods for treating a coronavirus infection. For example, treatment may be effected by administering a neurotransmitter inhibitor, a signaling kinase inhibitor, an estrogen receptor inhibitor, a DNA metabolism inhibitor or an anti-parasitic agent. Also provided are methods for treating a coronavirus infection in which an anti-viral drug also is administered during any of the described methods.

Claims (9)

1. A method for treating a coronavirus infection in a subject, comprising the step of:

administering to said subject a therapeutically effective amount of a kinase signaling inhibitor selected from the group consisting of imatinib mesylate, nilotinib hydrochloride and dasatinib.

2. The method of claim 1 , wherein said coronavirus is Middle East respiratory syndrome coronavirus or severe acute respiratory syndrome coronavirus.

3. The method of claim 1 , wherein said kinase signaling inhibitor inhibits viral activity by at least 50%.

4. The method of claim 1 , wherein said kinase signaling inhibitor inhibits viral RNA production and/or blocks endosomal fusion.

5. The method of claim 1 , wherein said kinase signaling inhibitor is administered in a concentration range of about 50 mg/kg to about 500 mg/kg per day.

6. The method of claim 1 , further comprising:

administering an antiviral drug.

7. The method of claim 6 , wherein said antiviral drug is selected from the group consisting of an interferon, ribavirin, adefovir, tenofovir, acyclovir, brivudin, cidofovir, fomivirsen, foscarnet, ganciclovir, penciclovir, amantadine, rimantadine and zanamivir.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2016
From: FRIEMAN, MATTHEW
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 040244/0577 →
CONFIRMATORY LICENSE Recorded Oct 19, 2016
From: UNIVERSITY OF MARYLAND BALTIMORE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040056/0631 →
Continuity (2)
Provisional Application 61976031 · Apr 7, 2014
Related Publication 20170027975A1 · Feb 2, 2017
Cited By (2)
US 12,324,441 US 12,667,583